Levetiracetam Brillpharma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a key role in neurotransmitter release. By modulating SV2A activity, the drug stabilises neuronal firing and reduces excessive excitatory signaling, thereby lowering the likelihood of seizure propagation.

The specific dose of Levetiracetam Brillpharma is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimising adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It generally has fewer drug‑enzyme interactions, a favorable tolerability profile, and does not require routine therapeutic drug monitoring, making it a convenient option for many patients.

Levetiracetam Brillpharma should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability throughout its shelf life.

Levetiracetam Brillpharma is administered orally, typically as a tablet taken with or without food. The exact dosing schedule—once daily, twice daily, or more—depends on the prescriber’s assessment of the patient’s clinical needs and response to therapy.

Serious risks include severe allergic reactions such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, blood disorders (e.g., neutropenia), hepatic dysfunction, and the emergence of suicidal thoughts or behaviors. Patients should be monitored closely for any of these events and seek immediate medical attention if they occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric disorders, or those taking enzyme‑inducing antiepileptics that may markedly reduce levetiracetam levels.